Base de dados : MEDLINE
Pesquisa : D02.145.074.722 [Categoria DeCS]
Referências encontradas : 2708 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 271 ir para página                         

  1 / 2708 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873551
[Au] Autor:Cirlini M; Demuth TM; Biancardi A; Rychlik M; Dall'Asta C; Bruni R
[Ad] Endereço:Department of Food and Drug - LS9 Interlab Group, University of Parma, Via G.P. Usberti 95/a, 43134 Parma, Italy.
[Ti] Título:Are tropane alkaloids present in organic foods? Detection of scopolamine and atropine in organic buckwheat (Fagopyron esculentum L.) products by UHPLC-MS/MS.
[So] Source:Food Chem;239:141-147, 2018 Jan 15.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A closer monitoring of tropane alkaloids (TA) in foods is now recommended by the European Commission, following a series of alerts related to the contamination of buckwheat with weeds of the genus Datura. A novel, accurate UHPLC-MS/MS method was developed and validated for the rapid detection of scopolamine and atropine in buckwheat foods. A suitable extraction protocol was set up to maximize recoveries and detection limits in different raw, processed and baked foods. The method offers good performances in terms of sensitivity, accuracy and precision, with LOQs at 0.04 and 0.10µg/kg. The established method is suitable for routine determination of trace levels of TA and was applied to 26 different buckwheat-derived organic foods, detecting TA in 3 samples (13.9-83.9µg/kg for atropine and 5.7-10.4µg/kg for scopolamine). Only in one case the level of contamination was relevant in terms of food safety.
[Mh] Termos MeSH primário: Alimentos Orgânicos
[Mh] Termos MeSH secundário: Alcaloides
Atropina
Cromatografia Líquida de Alta Pressão
Fagopyrum
Seres Humanos
Hidrobrometo de Escopolamina
Espectrometria de Massas em Tandem
Tropanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Tropanes); 451IFR0GXB (Scopolamine Hydrobromide); 7C0697DR9I (Atropine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE


  2 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28734777
[Au] Autor:Krout D; Pramod AB; Dahal RA; Tomlinson MJ; Sharma B; Foster JD; Zou MF; Boatang C; Newman AH; Lever JR; Vaughan RA; Henry LK
[Ad] Endereço:Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, 1301 North Columbia Road, Grand Forks, ND 58202, USA.
[Ti] Título:Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs.
[So] Source:Biochem Pharmacol;142:204-215, 2017 Oct 15.
[Is] ISSN:1873-2968
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dopamine transporter (DAT) blockers like cocaine and many other abused and therapeutic drugs bind and stabilize an inactive form of the transporter inhibiting reuptake of extracellular dopamine (DA). The resulting increases in DA lead to the ability of these drugs to induce psychomotor alterations and addiction, but paradoxical findings in animal models indicate that not all DAT antagonists induce cocaine-like behavioral outcomes. How this occurs is not known, but one possibility is that uptake inhibitors may bind at multiple locations or in different poses to stabilize distinct conformational transporter states associated with differential neurochemical endpoints. Understanding the molecular mechanisms governing the pharmacological inhibition of DAT is therefore key for understanding the requisite interactions for behavioral modulation and addiction. Previously, we leveraged complementary computational docking, mutagenesis, peptide mapping, and substituted cysteine accessibility strategies to identify the specific adduction site and binding pose for the crosslinkable, photoactive cocaine analog, RTI 82, which contains a photoactive azide attached at the 2ß position of the tropane pharmacophore. Here, we utilize similar methodology with a different cocaine analog N-[4-(4-azido-3-I-iodophenyl)-butyl]-2-carbomethoxy-3-(4-chlorophenyl)tropane, MFZ 2-24, where the photoactive azide is attached to the tropane nitrogen. In contrast to RTI 82, which crosslinked into residue Phe319 of transmembrane domain (TM) 6, our findings show that MFZ 2-24 adducts to Leu80 in TM1 with modeling and biochemical data indicating that MFZ 2-24, like RTI 82, occupies the central S1 binding pocket with the (+)-charged tropane ring nitrogen coordinating with the (-)-charged carboxyl side chain of Asp79. The superimposition of the tropane ring in the three-dimensional binding poses of these two distinct ligands provides strong experimental evidence for cocaine binding to DAT in the S1 site and the importance of the tropane moiety in competitive mechanisms of DA uptake inhibition. These findings set a structure-function baseline for comparison of typical and atypical DAT inhibitors and how their interactions with DAT could lead to the loss of cocaine-like behaviors.
[Mh] Termos MeSH primário: Cocaína/análogos & derivados
Proteínas da Membrana Plasmática de Transporte de Dopamina/antagonistas & inibidores
Transtornos Relacionados ao Uso de Substâncias/metabolismo
Tropanos/metabolismo
[Mh] Termos MeSH secundário: Animais
Azidas/química
Azidas/metabolismo
Sítios de Ligação
Cocaína/química
Cocaína/metabolismo
Reagentes para Ligações Cruzadas/química
Reagentes para Ligações Cruzadas/metabolismo
Proteínas da Membrana Plasmática de Transporte de Dopamina/química
Radioisótopos do Iodo
Células LLC-PK1
Ligantes
Simulação de Acoplamento Molecular
Simulação de Dinâmica Molecular
Estrutura Molecular
Proteínas Mutantes/química
Proteínas Mutantes/metabolismo
Mapeamento de Peptídeos
Marcadores de Fotoafinidade
Ligação Proteica
Relação Estrutura-Atividade
Transtornos Relacionados ao Uso de Substâncias/psicologia
Suínos
Tropanos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Azides); 0 (Cross-Linking Reagents); 0 (Dopamine Plasma Membrane Transport Proteins); 0 (Iodine Radioisotopes); 0 (Ligands); 0 (Mutant Proteins); 0 (N-(4-(4-azido-3-(125I)iodophenyl)butyl)-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane); 0 (Photoaffinity Labels); 0 (Tropanes); 141782-67-4 (RTI 82); I5Y540LHVR (Cocaine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170724
[St] Status:MEDLINE


  3 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28595287
[Au] Autor:Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K; PARS Investigators
[Ad] Endereço:Institute for Neurodegenerative Disorders, New Haven, Connecticut.
[Ti] Título:Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
[So] Source:JAMA Neurol;74(8):933-940, 2017 Aug 01.
[Is] ISSN:2168-6157
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Detecting individuals at risk for Parkinson disease (PD) during the prodromal phase could clarify disease mechanisms and allow for treatment earlier in the disease process to possibly slow or prevent the onset of motor PD. Objective: To determine if the combination of smell identification testing followed by dopamine transporter (DAT) imaging can accurately and efficiently identify individuals from the general population at risk for conversion to a clinical diagnosis of PD. Design, Setting, and Participants: Participants were identified from the community by olfactory testing assessed longitudinally with DAT imaging 2 and 4 years after baseline and by annual clinical follow-up to determine whether they had clinical evidence to establish a PD diagnosis. Participants were contacted by mail and completed olfactory testing at home. Longitudinal follow-up of clinical measures and DAT imaging occurred at specialty centers. There were 203 hyposmic and 100 normosmic participants. A total of 185 hyposmic and 95 normosmic individuals had at least 1 follow-up visit, and 152 hyposmic participants (82.2%) were either observed for 4 years or converted to PD during follow-up. Main Outcomes and Measures: Percentage of individuals with hyposmia and a DAT deficit that converted to PD and the change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imaging during 4-year follow-up. Results: Of 280 total participants, 140 (50.0%) were male, and the mean (SD) age of the cohort was 63 (8.7) years. Among 21 participants with hyposmia and a DAT deficit (65% or less of age-expected lowest putamen binding ratio) at baseline, 14 (67%) converted to PD at 4 years compared with 2 of 22 participants (9%) with a DAT in an indeterminate range (greater than 65%-80%) and 3 of 109 participants (2.8%) with no DAT deficit (greater than 80%) at baseline. Individuals with a baseline DAT deficit experienced a 4-year decline in DAT binding of 20.23% (SD, 15.04%) compared with 3.68% (SD, 18.36%) and 5.45% (SD, 13.58%) for participants with an indeterminate and no DAT deficit, respectively (P = .002). The relative risk of conversion to a diagnosis of PD in hyposmic individuals with a DAT deficit was 17.47 (95% CI, 7.02-43.45) compared with individuals with either indeterminate or no DAT deficit. Conclusions and Relevance: The combination of hyposmia and DAT deficit was highly predictive of conversion to PD within 4 years of clinical follow-up. Individuals with hyposmia and a DAT deficit had a 5% reduction in DAT binding annually, similar to early PD. These results provide a framework for planning disease prevention studies in PD.
[Mh] Termos MeSH primário: Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Transtornos do Olfato/diagnóstico por imagem
Doença de Parkinson/diagnóstico por imagem
Sintomas Prodrômicos
[Mh] Termos MeSH secundário: Idoso
Distribuição de Qui-Quadrado
Estudos de Coortes
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Tomografia Computadorizada de Emissão de Fóton Único
Tropanos/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Tropanes); 155797-99-2 (2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1001/jamaneurol.2017.0985


  4 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28551239
[Au] Autor:Martinello M; Borin A; Stella R; Bovo D; Biancotto G; Gallina A; Mutinelli F
[Ad] Endereço:National Reference Laboratory for Beekeeping, Istituto Zooprofilattico Sperimentale delle Venezie, Padova, Italy. Electronic address: mmartinello@izsvenezie.it.
[Ti] Título:Development and validation of a QuEChERS method coupled to liquid chromatography and high resolution mass spectrometry to determine pyrrolizidine and tropane alkaloids in honey.
[So] Source:Food Chem;234:295-302, 2017 Nov 01.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Awareness about pyrrolizidine alkaloids (PAs) and tropane alkaloids (TAs) in food was recently raised by the European Food Safety Authority stressing the lack of data and gaps of knowledge required to improve the risk assessment strategy. The present study aimed at the elaboration and validation of a method to determine PAs and TAs in honey. QuEChERS sample treatment and liquid chromatography coupled to hybrid high resolution mass spectrometry, were used. The method resulted in good linearity (R >0.99) and low limits of detection and quantification, ranging from 0.04 to 0.2µgkg and from 0.1 to 0.7µgkg respectively. Recoveries ranged from 92.3 to 114.8% with repeatability lying between 0.9 and 15.1% and reproducibility between 1.1 and 15.6%. These performances demonstrate the selectivity and sensitivity of the method for simultaneous trace detection and quantification of PAs and TAs in honey, verified through the analysis of forty commercial samples.
[Mh] Termos MeSH primário: Contaminação de Alimentos/análise
Mel/análise
Alcaloides de Pirrolizidina/análise
Tropanos/análise
[Mh] Termos MeSH secundário: Cromatografia Líquida
Reprodutibilidade dos Testes
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Pyrrolizidine Alkaloids); 0 (Tropanes)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170529
[St] Status:MEDLINE


  5 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28418820
[Au] Autor:Vale TC; de Lima Pinto FC; Pedroso JL; Alves Dos Reis M; Batista IR; Affonseca Bressan R; Magalhães Rivero RL; Mendonça RA; Barsottini OG
[Ad] Endereço:From the Department of Internal Medicine, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil (T.C.V.); Department of Neurology (F.C.d.L.P., J.L.P., O.G.B.) and Department of Psychiatry, Laboratório Interdisciplinar de Neurociências Clínicas (LiNC) (M.A.d.R., I.R.B., R.A.B.), Universidade Fed
[Ti] Título:Case 241: Hemiparkinsonism- Hemiatrophy-SPECT with Tc TRODAT-1 and Muscle MR Imaging Abnormalities.
[So] Source:Radiology;283(2):613-619, 2017 May.
[Is] ISSN:1527-1315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:History A 43-year-old right-handed man presented with a history of progressive mild left-sided weakness and slowness of movements. Symptoms began 4 years earlier, and the patient noticed a progressive decline in his daily routine due to gait difficulties in the past year. There was no history of head trauma, surgery, drug therapy, smoking, or alcohol abuse, nor was there any relevant family history. Examination revealed normal cognition (29 of 30 points on the Mini-Mental State Examination and 27 of 30 points on the Montreal Cognitive Assessment) and normal cerebellar, sensory, cranial nerve, and autonomic function. There was mild left-sided weakness involving the upper and lower limbs (medical research council graded muscle strength as 4+ out of 5) that was associated with facial hypomimia and a rigid akinetic syndrome only in the patient's left hemibody (Unified Parkinson's Disease Rating Scale [UPDRS] part III [motor examination], 23 out of 52 points). Mild atrophy in the left upper and lower limbs without pain, swelling, or skin lesions was noted at physical examination. Routine blood chemistry was normal, as were serum creatine kinase and aldolase levels and thyroid, hepatic, and renal function. T1- and T2-weighted, fluid-attenuated inversion recovery, diffusion- and perfusion-weighted, and contrast material-enhanced brain magnetic resonance (MR) imaging results were normal, without basal ganglia hyperintensity, lacunae, calcification, or heavy metal deposits. Muscle MR imaging and single photon emission computed tomography (SPECT) with technetium 99m ( Tc) tropane dopamine transporter (TRODAT)-1 were performed for further evaluation. This patient received levodopa and benserazide (200 and 50 mg, respectively) four times a day and amantadine (100 mg) three times a day without adequate improvement (UPDRS score decreased from 23 to 20 points).
[Mh] Termos MeSH primário: Imagem por Ressonância Magnética/métodos
Atrofia Muscular/diagnóstico por imagem
Compostos de Organotecnécio
Paresia/diagnóstico por imagem
Transtornos Parkinsonianos/diagnóstico por imagem
Tomografia Computadorizada de Emissão de Fóton Único/métodos
Tropanos
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Seres Humanos
Masculino
Compostos Radiofarmacêuticos
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Organotechnetium Compounds); 0 (Radiopharmaceuticals); 0 (Tropanes); 0 (technetium Tc 99m TRODAT-1)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1148/radiol.2017151717


  6 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28382589
[Au] Autor:Yamamoto H; Arimura S; Nakanishi A; Shimo Y; Motoi Y; Ishiguro K; Murakami K; Hattori N; Aoki S
[Ad] Endereço:Department of Radiology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
[Ti] Título:Age-related effects and gender differences in Japanese healthy controls for [ I] FP-CIT SPECT.
[So] Source:Ann Nucl Med;31(5):407-412, 2017 Jun.
[Is] ISSN:1864-6433
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Dopamine transporter (DAT) imaging with [ I]FP-CIT (DaTSCAN) is a widely used diagnostic tool for Parkinsonism and dementia. Since it was approved by the Japanese Ministry of Health, Labor, and Welfare in 2013, there have been no articles focusing on a Japanese normal population. The aim of this study was to examine the effect of aging and gender on DAT availability in Japanese people. METHODS: SPECT imaging of 30 healthy Japanese controls (17 males, 13 females; range 50-86 years, mean 70 years) was performed. SPECT images were reconstructed using a three-dimensional order subset expectation maximization (OSEM) algorithm with correction of the point spread function and scatter correction, without attenuation correction. The specific binding ratio (SBR) was calculated by DATview software. Statistical analyses were performed using linear regression analysis, analysis of variance, and multiple comparison analysis. RESULTS: A strong correlation between the SBR and age was observed. The correlation coefficient in males and females were -0.566 and -0.502, respectively. The analysis of variance revealed that aging led to a decline of the SBR, and a significant difference (p = 0.005) was observed among generations. Gender also affected the SBR, and there was a significant difference between males and females (p = 0.036). The SBR in females was higher than in males. Consequently, the multiple comparison revealed a significant difference between 50s and 70s (p = 0.015) and 50s and 80s (p = 0.006). CONCLUSIONS: This is the first [ I]FP-CIT SPECT study on subjects with normal dopamine function in Asian countries. This study provides a database of [ I]FP-CIT SPECT in Japanese healthy controls. Higher DAT availability was found in women than in men. An average age-related decline in DAT availability of 8.9% was found in both genders. The data collected in this study would be helpful for Japanese physicians to make a differential diagnosis in Parkinsonian syndrome. The registration identification number for this study is UMIN000018045.
[Mh] Termos MeSH primário: Envelhecimento/metabolismo
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Voluntários Saudáveis
Caracteres Sexuais
Tomografia Computadorizada de Emissão de Fóton Único
Tropanos/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Japão
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Tropanes); 155797-99-2 (2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1007/s12149-017-1168-1


  7 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28361209
[Au] Autor:Shimizu S; Hirose D; Namioka N; Kanetaka H; Hirao K; Hatanaka H; Takenoshita N; Kaneko Y; Ogawa Y; Umahara T; Sakurai H; Hanyu H
[Ad] Endereço:Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. soichiroshimizu@gmail.com.
[Ti] Título:Correlation between clinical symptoms and striatal DAT uptake in patients with DLB.
[So] Source:Ann Nucl Med;31(5):390-398, 2017 Jun.
[Is] ISSN:1864-6433
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: It is widely known that there is low striatal I-FP-CIT dopamine transporter-single photon emission tomography (DAT-SPECT) uptake in patients with dementia with Lewy bodies (DLB). We assessed the correlation between symptom and regional low DAT uptake in the striatum. METHODS: Patients with Alzheimer's disease (AD) (n = 95) and patients with DLB (n = 133) who underwent DAT-SPECT were enrolled. We examined the correlation between symptoms [cognitive function decline, fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD)] and regional striatal DAT uptake in the patients with DLB. RESULTS: When comparing the DLB patients with or without fluctuations, visual hallucinations, or RBD, there were no significant differences in DAT uptake in any regions of the striatum. DLB patients with parkinsonism had significantly lower DAT uptake in entire striatum, entire putamen, and anterior putamen compared to DLB patients without parkinsonism. Moreover, there was weak but significant correlation between severity of parkinsonism and DAT uptake in entire regions of the striatum in patients with DLB. There was no significant correlation between cognitive function and DAT uptake in any regions of the striatum in patients with DLB. CONCLUSIONS: In patients with DLB, only parkinsonism is associated with a reduction in striatal DAT uptake.
[Mh] Termos MeSH primário: Doença por Corpos de Lewy/metabolismo
Neostriado/metabolismo
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Transporte Biológico
Cognição
Feminino
Seres Humanos
Doença por Corpos de Lewy/diagnóstico por imagem
Doença por Corpos de Lewy/fisiopatologia
Masculino
Tomografia Computadorizada de Emissão de Fóton Único
Tropanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tropanes); 155797-99-2 (2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.1007/s12149-017-1166-3


  8 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28330956
[Au] Autor:Li Y; Kang W; Yang Q; Zhang L; Zhang L; Dong F; Chen S; Liu J
[Ad] Endereço:From the Department of Neurology and Institute of Neurology (Y.L., W.K., Q.Y., Linyuan Zhang, F.D., S.C., J.L.), Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine; Department of Neurology (W.K.), Ruijin Hospital North affiliated to Shanghai Jiaotong University School of M
[Ti] Título:Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases.
[So] Source:Neurology;88(16):1493-1500, 2017 Apr 18.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the predictive value of clinical assessment and dopamine transporter (DAT) uptake for the early development of neurodegenerative synucleinopathy diseases from idiopathic REM sleep behavior disorder (iRBD) over 5 years in a Chinese population. METHODS: Forty-three patients with iRBD were administered clinical assessment tests, and 35 were examined by DAT-SPECT imaging during 2011. Cox proportional hazard and Kaplan-Meier analyses were used to evaluate the predictive value of the markers in a follow-up study over 5 years. RESULTS: Eighteen patients (41.9%) developed neurodegenerative synucleinopathy diseases after a median of 4.1 years of prospective follow-up (median interval of 10.5 years from the estimated onset of iRBD symptoms). Patients with higher scores on the Nonmotor Symptom Questionnaire (hazard ratio [HR] 3.11, 95% confidence interval [CI] 1.15-8.40, = 0.026) and Scale for Outcomes in Parkinson Disease-Autonomic questionnaire (HR 4.46, 95% CI 1.64-12.10, = 0.003) were more likely to develop neurodegenerative synucleinopathy diseases. Furthermore, the population with decreased Tc-TRODAT-1 binding in the left striatum (HR 2.7, 95% CI 1.02-7.14, = 0.046) and putamen (HR 3.23, 95% CI 1.16-8.33, = 0.024) had a relatively higher risk of developing neurodegenerative synucleinopathy diseases. CONCLUSIONS: Our findings elucidate the predictive value of autonomic dysfunction and DAT uptake in identifying patients with iRBD at a high risk of progressing into neurodegenerative synucleinopathy diseases and could form a basis for future disease-prevention trials.
[Mh] Termos MeSH primário: Encéfalo/diagnóstico por imagem
Doenças Neurodegenerativas/diagnóstico por imagem
Transtorno do Comportamento do Sono REM/diagnóstico por imagem
Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Idoso
Mapeamento Encefálico
China
Progressão da Doença
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Compostos de Organotecnécio
Prognóstico
Modelos de Riscos Proporcionais
Estudos Prospectivos
Compostos Radiofarmacêuticos
Inquéritos e Questionários
Tropanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Organotechnetium Compounds); 0 (Radiopharmaceuticals); 0 (Tropanes); 0 (technetium Tc 99m TRODAT-1)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170502
[Lr] Data última revisão:
170502
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000003838


  9 / 2708 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28320195
[Au] Autor:Yoshii F; Ryo M; Baba Y; Koide T; Hashimoto J
[Ad] Endereço:Department of Neurology, Tokai University Oiso Hospital, 21-1 Gakkyou, Oiso, Naka-gun 259-0198, Japan. Electronic address: yoshii@is.icc.u-tokai.ac.jp.
[Ti] Título:Combined use of dopamine transporter imaging (DAT-SPECT) and I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease.
[So] Source:J Neurol Sci;375:80-85, 2017 Apr 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To examine whether combined use of I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) and I-MIBG myocardial scintigraphy (MIBG) is superior to either modality alone for diagnosing Parkinson's disease (PD). METHODS: Patients with probable PD (n=120) who underwent both DAT-SPECT and MIBG myocardial scintigraphy within short intervals were enrolled. Specific binding ratio (SBR) of DAT-SPECT images and heart-to-mediastinum (H/M) ratio of MIBG images were used as quantitative measures. We classified patients into 4 groups based on SBR value and H/M ratio, or into two groups based on the striatal asymmetry index (SAI) of DAT-SPECT, and examined the clinical features of each group. We also investigated the characteristics of SWEDDs (scans without evidence of dopaminergic deficits) patients. Finally, we calculated the sensitivity and specificity of each method and the combined method. RESULTS: SBR value was significantly correlated with both early and delayed H/M ratio values. Motor complications and hallucinations were observed at high frequency in the group with both lower SBR and H/M ratio, and hallucinations appeared in the group with larger SAI. SWEDDs were observed 8.3% of patients. The sensitivity and specificity of diagnosing PD were 91.7% and 15.0% by SBR of DAT-SPECT, 78.3% and 90.0% by H/M ratio of MIBG uptake, and 74.2% and 95.0% by the combined modalities, respectively. CONCLUSIONS: Combined use of DAT-SPECT and MIBG myocardial scintigraphy increases the specificity of PD diagnosis, and is helpful for understanding the clinical features or predicting complications.
[Mh] Termos MeSH primário: 3-Iodobenzilguanidina/farmacocinética
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Imagem de Perfusão do Miocárdio
Doença de Parkinson/diagnóstico por imagem
Tropanos/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Estatística como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Tropanes); 155797-99-2 (2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane); 35MRW7B4AD (3-Iodobenzylguanidine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE


  10 / 2708 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28235579
[Au] Autor:Chernova E; Sidelev S; Russkikh I; Voyakina E; Babanazarova O; Romanov R; Kotovshchikov A; Mazur-Marzec H
[Ad] Endereço:Saint-Petersburg Scientific Research Centre for Ecological Safety, Russian Academy of Sciences, Korpusnaya str., 18, Saint-Petersburg, 197110, Russia. Electronic address: s3561389@yandex.ru.
[Ti] Título:Dolichospermum and Aphanizomenon as neurotoxins producers in some Russian freshwaters.
[So] Source:Toxicon;130:47-55, 2017 May.
[Is] ISSN:1879-3150
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Last decades, cyanobacterial blooms have been commonly reported in Russia. Among the boom-forming species, potential toxin producers have been identified. The aim of this paper was to study the presence of neurotoxic compounds - saxitoxins and anatoxin-a - in water bodies from different regions of Russia. We also made attempts to identify the neurotoxin-producing genera. The good convergence of the results obtained by light microscopy, PCR and LC-MS/MS analyses indicated the presence of active neurotoxin producing species in all investigated water bodies. Saxitoxin was detected in phytoplankton from 4 water bodies in Central European Russia and West Siberia, including lake and reservoirs used as a source for potable water. The water bodies differed with the respect of saxitoxin producers which belonged to Aphanizomenon and/or Dolichospermum genera. For the first time, we obtained quantitative data on the intracellular saxitoxin concentration in Russian freshwaters using LC-MS/MS. Anatoxin-a was detected only in lakes of Northwestern Russia. In the eutrophic shallow Lower Suzdal Lake, Aphanizomenon was the stated anatoxin-a-producing genus. In the large shallow artificial hypertrophic Sestroretskij Razliv Lake, it was very likely that both dominant species - Aphanizomenon flos-aquae and Dolichospermum planctonicum - were anatoxin-a producers.
[Mh] Termos MeSH primário: Aphanizomenon/metabolismo
Cianobactérias/metabolismo
Água Doce/química
Neurotoxinas/metabolismo
[Mh] Termos MeSH secundário: Aphanizomenon/genética
Aphanizomenon/isolamento & purificação
Cromatografia Líquida
Cianobactérias/genética
Cianobactérias/isolamento & purificação
Monitoramento Ambiental
Água Doce/microbiologia
Espectrometria de Massas
Neurotoxinas/química
Neurotoxinas/isolamento & purificação
Federação Russa
Saxitoxina/química
Saxitoxina/isolamento & purificação
Saxitoxina/metabolismo
Tropanos/química
Tropanos/isolamento & purificação
Tropanos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neurotoxins); 0 (Tropanes); 35523-89-8 (Saxitoxin); 80023A73NK (anatoxin a)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170226
[St] Status:MEDLINE



página 1 de 271 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde